DNMT3A mutations are frequent in cytogenetically normal acute myeloid leukemia (cn-AML) patients and associated with poor survival. The role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in DNMT3A mut cn-AML patients remains unclear. In this study, we retrospectively analyzed the prognostic impact of DNMT3A mutations and explored the role of allo-HSCT in 308 cn-AML patients who received consolidation of intensive chemotherapy or allo-HSCT in our center from March 2005 to May 2014. In the whole cohort, 63 patients (20.5%) were identified with DNMT3A exon 23 mutations and R882H was the most frequent variant. DNMT3A mut patients had shorter overall survival (3-year OS: 31.9% vs. 52.0%, P 5 0.009) and disease-free survival (3-year DFS: 21.8% vs. 40.1%, P 5 0.004) compared with DNMT3A wt patients. Based on FLT3/NPM1/CEBPA mutations, 308 cn-AML patients were divided into favorable/intermediate group (n 5 262) and unfavorable group (n 5 46). There were no significant differences in 3-year OS and 3-year DFS between DNMT3A mut and DNMT3A wt patients in both favorable/intermediate and unfavorable groups. Additionally, in multivariate analysis, DNMT3A mutation remained an independent adverse prognostic factor for the survival. In the DNMT3A mut cohort, 23 complete remission (CR) patients received allo-HSCT consolidation and 32 CR patients received chemotherapy consolidation, dramatic differences were observed in 3-year OS (51.7% vs. 28.9%, P 5 0.048) and 3-year DFS (41.6% vs. 14.9%, P 5 0.024) between allo-HSCT group and chemotherapy group. Collectively, DNMT3A mutation is a poor prognostic factor for cn-AML patients and allo-HSCT could improve survival of cn-AML patients with DNMT3A mutations. 
Introduction
Acute myeloid leukemia (AML) is a heterogeneous disorder with regard to morphology and chromosome aberrations detected in the leukemic cells. Clinical and genetic prognostic markers are now crucial in the evaluation of AML patients and in guiding rational management. Forty to fifty percent of patients do not have clonal chromosomal aberrations, and all such cases of cytogenetically normal AML (cn-AML) are currently categorized in the intermediate-risk group [1, 2] . In recent years, extended molecular analyses have yielded novel molecular markers important for proper diagnostics and prognostics of AML, including fms-like tyrosine kinase-3 gene (FLT3), nucleophosmin gene (NPM1), and the CCAAT/enhancer binding protein gene (CEBPA), which provide risk classification for AML at diagnosis in current clinical practice [3] [4] [5] [6] .
With the development of whole genome sequencing technology, additional recurrently mutated genes in AML were identified. Many of the mutated genes were involved in epigenetic regulation of transcription, including IDH1/2, TET-2, and DNMT3A [7] [8] [9] [10] [11] . DNMT3A, located in chromosomal band 2p23 and, together with DNMT3B and DNMT1, is a member of a DNA methyltransferase (MTase) family, which catalyzes the addition of methyl groups to cytosine residues of CpG nucleotides [12] . According to published literatures, a range of 11-35% AML patients were observed with DNMT3A mutations and the majority of DNMT3A mutations were missense mutations at residue 882. DNMT3A mutations were also associated with old age, higher white blood cells, normal cytogenetic, and the presence of NPM1, FLT3-ITD, and IDH1 mutations [13] [14] [15] [16] . The function and biological consequences of DNMT3A mutations have not yet to be fully understood, while a negative impact on outcomes in cn-AML patients was observed by a number of studies [17] [18] [19] [20] [21] . Currently, only three molecular markers (NPM1, CEBPA, and FLT3-ITD) have been included in the European Leukemia Net classification [6] , whether DNMT3A will be included in the future is an interesting question. Moreover, allogeneic hematopoietic stem cell transplantation (allo-HSCT) were recommended to be the first-front therapy for the consolidation of AML patients with molecular unfavorable factors [6, 22, 23] , however, the clinical benefit of allo-HSCT consolidation has not been clearly established in cn-AML patients with DNMT3A mutations.
As the DNMT3A often served as the poor risk factor and R882 mutations was the major mutation, we analyzed DNMT3A R882 mutations together with FLT3, NPM1, and CEBPA to provide risk classification, and retrospectively analyzed the clinical phenotype, prognostic impact of DNMT3A mutations and explored treatment value of allo-HSCT in 308 cn-AML patients who received intensive consolidation therapy or allo-HSCT.
Patients and Methods
Patients and treatments. Three hundred and eight adult patients diagnosed with de novo cn-AML were involved in this study with approval of the ethics committee of our hospital from HSCT patients received a conditioning regimen consisting of cytarabine (2 g/ m 2 /day for 2 days), busulfan (3.2 mg/kg/day for 3 days, intravenously), and cyclophosphamide (1.8 g/m 2 /day for 2 days). Patients with high risk of central nervous system leukemia received a similar regimen, but with total body irradiation (8 Gy, lung shielding at 6.5 Gy, on Day -6) substituted for busulfan and cytarabine started on Day -8. The patients who are considered poor candidates for myeloablative conditioning due to advanced age or other concurrent medical conditions were conditioned with fludarabine 30 mg/m 2 (Days -6 to -2), cytarabine 2 g/day (on Days -5 and -2), rabbit antithymocyte globulin (ATG; Genzyme, Cambridge, MA) 1.5 mg/kg/day (on Days -5 to -2), and cyclophosphamide 30 mg/kg/day (on Days -3 to -2). Graft-versus-host disease (GVHD) prophylaxis consisted of continuous cyclosporine infusion at 3 mg/kg/day starting on Day -1 until patients could switch to oral intake (PO), with a target blood concentration ranging from 200 to 300 ng/ml, and short term methotrexate given on Days 11, 13, 16 , and 111 at doses of 15, 10, 10, and 10 mg/m 2 , respectively.
Cytogenetic and mutation analyses. The bone marrow (BM) samples of de novo AML patients were processed using standard 24-hr unstimulated cultures. A conventional R-banding assay was used for karyotypic analysis. When possible, at least 20 metaphases per sample were analyzed. Genomic DNA was extracted from BMderived mononuclear cells using the PurelinkTM Genomic DNA mini kit (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. A variety of acute leukemia-related gene mutations were evaluated, including FLT3-ITD, FLT3-TKD, NPM1, CEBPA, and DNMT3A. In this study, only DNMT3A exon 23 mutations were analyzed. The gene mutations were detected by PCR amplification of the entire or a portion of the coding region followed by direct bidirectional DNA sequencing in cn-AML patients.
Statistical analyses. A student's t-test was used to compare the age, WBC (white blood cells) count, hemoglobin, platelet count, and BM blasts at diagnosis in the different groups. The v 2 test was used to analyze the interrelation for different gene mutations. Overall survival (OS) was measured as the time from the date of disease diagnosis to the date of death or last follow-up. Disease-free survival (DFS) was defined as the time from disease diagnosis to CR, first relapse, or death. A KaplanMeier analysis was used to calculate the distribution of OS and DFS. All quoted P values were from two-tailed tests and confidence intervals refer to 95% boundaries. All calculations were performed using the SPSS software package (version 19.0; IBM). 
Results

Clinical characteristics of the 308 cn-AML patients
Frequencies of DNMT3A mutations and clinical features in cn-AML patients
As shown in Table I , 63 (20.4%) cn-AML patients were identified with DNMT3A exon 23 mutations in a total cohort of 308 cn-AML patients, and the distribution of mutations was as follows: R882H (n 5 36), R882C (n 5 12), R882P (N 5 6), R882H&C (n 5 2), and others (n 5 7). The median age of DNMT3A mutated patients was elder than that of the control group (P < 0.001), while there were no significant differences in sex, white cell counts, and blast percentage in peripheral blood (PB) and BM between patients with and without DNMT3A mutations. However, regarding to FAB distributions, more M5 patients (38.1%) were observed in DNMT3A mutated group compared with the controls (20.8%) group (P < 0.001). FLT3-ITD and NPM1 mutations were also more often observed in DNMT3A mutated group (P < 0.001).
Clinical outcome of cn-AML patients with DNMT3A mutations
The median follow-up time for cn-AML patients was 30 months (range: 6-98 months We then performed multivariate analyses including age (<45 years vs. >45 years), treatment (allo-HSCT vs. chemotherapy), white blood cell counts, hemoglobin counts, platelet counts, ECOG score, FLT3-ITD/NPM1/CEBPA risk classification, and DNMT3A mutations on the end point OS and DFS in the total 308 cn-AML patients. The results revealed that age, treatment, FLT3-ITD/NPM1/CEBPA risk classification, and DNMT3A mutations were significantly and independently associated with a worse OS and DFS, while high white blood cell counts were associated with a worse OS and DFS and low ECOG score was associated with a better DFS in univariate analysis (Table II) .
allo-HSCT could improve survival of cn-AML with DNMT3A mutations
Fifty-five (55/63, 87.3%) DNMT3A mutated patients finally achieved CR with induction therapy. In these patients, 23 patients received allo-HSCT consolidation while 32 patients received at least four cycles of high-dose cytarabine-based combination chemotherapy. No significant differences were observed in age, sex, FAB distribution, BM blast, and other mutations in these two groups (Supporting Information). Interestingly, the 3-year OS (51.7% vs. 28.9%, P 5 0.048) and 3-year DFS (41.6% vs. 14.9%, P 5 0.024) were dramatically improved in allo-HSCT group. When we limited this comparison to the favorable/intermediate risk group only, significant differences were also observed in both 3-year OS (56.0% vs. 34.8%; P 5 0.036) and 3-year DFS (41.9% vs. 16.7%; P 5 0.047) between these two groups (Fig. 2) . Meanwhile, based on DNMT3A mutations, the total HSCT cohort (n 5 214) were further divided into DNMT3A wt group (n 5 189) and DNMT3A mut group (n 5 25) and the patients characteristic were listed in Supporting Information. No differences were observed in age, donor type, condition regimen, GVHD prophylaxis between two groups, and the 3-year OS (46.7% vs. 57.2%, P 5 0.731) and 3-year DFS (35.2% vs. 38.5%, P 5 0.871) were similar in these two groups. In addition, with respect to favorable/intermediate risk group, there were also no differences in 3-year OS (52.7% vs. 59.1%; P 5 0.599) and 3-year DFS (39.4% vs. 40.7%; P 5 0.569) between DNMT3A wt and DNMT3A mut groups (Supporting Information). These results might indicate that allo-HSCT could reverse the poor outcome of cn-AML with DNMT3A mutations. 
Discussions
Somatic DNA methyl transferase 3A (DNMT3A) mutations are recurrent molecular aberrations in AML and associated with poor survival. In a cohort of 308 cn-AML patients, our data showed that DNMT3A mutations were among the most common mutations in cn-AML, occurring in 20.4% of patients, with more frequency in older patients, and were significantly associated with NPM1 and FLT3-ITD mutations. Notably, Renneville et al. reported that in a 123 adult cn-AML cohort, 36 (29%) patients had DNMT3A mutations and 30 (83%) mutations affected the animo-acid residue R882 [16] . In this study, we found that there were no differences with respect to sex, BM blast percentage or WBC count between DNMT3A wt and DNMT3A mut cases, which was inconsistent with other reports [15, 16] . We speculated that the inconsistency might due to only DNMT3A exon23 mutated cases were included in this study. In addition, a series of studies have suggested that the presence of DNMT3A mutations in AML was associated with poor clinical outcomes. Thol et al. showed that DNMT3A mutations remained an independent negative prognostic marker for OS [15] . Marcucci et al. find adverse impact on OS in the subgroup analysis based on the age stratification [24] . In this report, we found that DNMT3A mutated cn-AML patients had shorter DFS and OS, and DNMT3A mutation remained an independent adverse prognostic factor for clinical outcome. Our study provided key insight into the prognostic value of DNMT3A mutations in cn-AML patients. However, it should be noted that DNMT3A non-R882 mutations were not included in this study. According to previous reports, non-R882 mutations accounted for minority of DNMT3A mutations (<40%), and the reason for the high prevalence of R882 was unclear [14] . It was reported that DNMT3A R882 and non-R882 mutations had different clinical implications in patients younger and older than 60 years of age [24] . Interestingly, Gaidzik et al. reported that in younger adults with AML DNMT3A R882 mutation was an unfavorable marker while non-R882 mutation was a favorable marker [25] .
As DNMT3A mutations often confer a poor prognosis in cn-AML, we further investigated whether or not allo-HSCT could reverse the poor survival of cn-AML with DNMT3A mutation. In this study, we found that allo-HSCT significantly improved the OS of cn-AML with DNMT3A mutation, and DNMT3A mut patients received allo-HSCT had the similar survival with the DNMT3A wt cn-AML patients. Dose intensified chemotherapy was reported to improve the outcome of the DNMT3A mutated cases [26] . However, several studies also showed that DNMT3A mutations did not have any effect on RFS and OS of patients who have undergone allo-HSCT [17, 26] . Our study might provide direct evidence for the benefit of allo-HSCT in DNMT3A mut cn-AML patients. In a recent publication, Bejar et al. used massively parallel sequencing to investigate 40 recurrent mutations and explored these mutations predict outcome after allo-HSCT in 87 patients with MDS, 16 patients with DNMT3A mutations (18%) were identified and DNMT3A mutations were associated with decreased OS [27] .
Integrated mutational profiling can improve initial risk stratification of AML patients, and the mutated genes with robust data supporting its independent prognostic value in AML patients could enter the integrated panel. To date, only NPM1, CEBPA, and FLT3-ITD mutations have entered clinical practice and affect risk stratification and treatment decision-making in cn-AML. Considering high occurrence and prognostic significance, it is likely that DNMT3A mutations belong to this category in cn-AML. In this study, we found that DNMT3A mutations were associated with FLT3-ITD and NPM1 [16] . In addition, Ribeiro et al. also found that DNMT3A mutations were independent factor for worse OS in their multivariate analysis including FLT3/NPM1 mutational status [17] . In this study, 211 patients (211/308, 68.5%) in this cohort were assigned to intermediate group and 46 patients (46/308, 15.0%) were assigned to unfavorable group. Most patients (214/308, 69.5%) patients of total cohort had received allo-HSCT treatment, which might improve survival of all cn-AML patients. Moreover, other gene mutations were likely to dictate both prognosis and potential therapeutic responsiveness in cn-AML. Pooling more clinical data in future and welldesigned clinical trial will be helpful to learn more about prognostic value of DNMT3A in combination other recurrent gene mutations in cn-AML patients.
DNMT3A is a key gene for the epigenetic regulation of human cells as the encoded enzyme is known to be a major player in the de novo DNA methylation at CpG sites. Much remains to be learned on the precise leukemogenic effect of the epigenetic changes caused by DNMT3A mutations. Recently, de novo AML patients with concurrent DNMT3A, FLT3, and NPM1 mutations had been suggested to represent a unique AML subset, and DNMT3A had a significant dominant effect on clinical outcomes of these subset patients [28] . It was reported that cells bearing mutations in DNMT3A but not NPM1 were present at diagnosis in AML patients and persist at remission and relapse. The results indicated that DNMT3A mut arises early in AML evolution, probably in HSCs, leading to a clonally expanded pool of preleukaemic HSCs from which AML evolves [29] . Interestingly, it was also reported that DNMT3A mutations presented in remission samples from 14 patients up to 8 years after initial AML diagnosis, and the presence of DNMT3A mutations in leukaemic blasts, but also at lower allele frequencies in T and B-cells from the same patients [30] . These results might provide a new insight into the role of DNMT3A in leukemogenic effect and management of AML therapy.
In conclusion, our results suggested that DNMT3A mutation was a poor prognostic factor for cn-AML patients and allo-HSCT could improve survival of cn-AML patients with DNMT3A mutations.
